NMN for Diabetes: Insulin Sensitivity and Blood Sugar Evidence

NMN is not an established treatment for diabetes. A small trial found improved muscle insulin sensitivity in selected women with prediabetes, but that result does not demonstrate diabetes reversal, reliable blood-sugar lowering or prevention of complications. A 2026 synthesis of randomized trials did not find significant overall improvements in fasting glucose or HbA1c ¹².

The distinction matters because “supports glucose metabolism” can sound like a treatment claim. NAD+ participates in metabolism; a supplement’s biological role does not show that adding it improves diabetes care. Start with how NMN, NR and NAD+ differ before interpreting a finding about one as evidence for all three.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD↗

What the often-cited prediabetes trial found

The 2021 Science study enrolled postmenopausal women with overweight or obesity and prediabetes. Twenty-five participants received NMN or placebo for ten weeks. Researchers measured insulin-stimulated glucose disposal using a specialized clamp procedure and found improvement with NMN, alongside changes in muscle insulin signaling ¹.

This was a meaningful research observation in a defined population. It was not a trial establishing that people with diagnosed type 2 diabetes can stop medication, reach remission or avoid kidney, eye or cardiovascular complications. Prediabetes is not interchangeable with every stage of diabetes, and a laboratory assessment of muscle insulin sensitivity is not the same outcome as a durable HbA1c improvement.

The study also cannot answer whether an injected NAD+ product would produce the same result. Route and molecule both differ. Our NMN efficacy guide places this trial among other outcomes rather than treating one favorable measurement as a general benefit.

What the larger evidence picture adds

A 2026 systematic review included fifteen randomized trials of oral NMN or related preparations. It found no significant pooled effect on fasting glucose or HbA1c; an insulin-resistance measure showed a non-significant downward trend with very low certainty. Trial durations were short, ranging from fourteen days to twenty-four weeks ².

The review’s interpretation is therefore narrower than either “NMN cures insulin resistance” or “all further research is pointless.” Current results do not establish broad glycemic benefit, while larger and longer disease-specific studies could clarify selected hypotheses. Short-term tolerability in trial participants also does not prove safety for every person with diabetes or its complications.

Does evidence for NR change the answer?

NR is another NAD+ precursor, not a substitute name for NMN. A twelve-week randomized trial in forty men with obesity and insulin resistance tested NR rather than NMN and did not establish improved insulin sensitivity ³. A separate small crossover study in overweight or obese adults found changes in NAD-related metabolites without improved insulin sensitivity ⁴.

These studies reinforce the importance of reading the product, population and outcome together. They should not be counted as extra successful NMN diabetes trials. Equally, raising NAD-related measurements in blood or muscle should not be described as equivalent to reducing average glucose, preventing diabetes progression or reducing medication requirements.

Our NR versus NMN comparison addresses the broader choice between precursors. This page focuses on the narrower question of diabetes and insulin sensitivity, where the expected clinical result needs to be specified.

NMN with metformin, insulin or a GLP-1 medicine

There is no established NMN regimen that can be substituted for a prescribed diabetes medicine. NIDDK describes diabetes treatment as dependent on diabetes type, glucose control and other health conditions; people with type 1 diabetes need insulin ⁵. A supplement purchase does not change that requirement.

Tell the treating team about the exact product and other ingredients before adding it. The relevant question is not just whether a database lists a known interaction. It is whether the proposed addition has a reason to be used, adequate safety information for your circumstances and a sensible monitoring plan. Our NMN and metformin review separates mechanistic ideas from demonstrated combination benefits.

For GLP-1 treatment, read NAD+ alongside GLP-1 medicines rather than assuming the combination has been validated because both are offered by a telehealth service. Do not change insulin or another diabetes medicine based on an expected supplement effect.

What about kidney disease and other complications?

Diabetes-related kidney, nerve and cardiovascular concerns need their own evidence. The prediabetes muscle study did not establish that NMN prevents those complications. Our kidney-health review distinguishes animal kidney findings from human outcomes; the neuropathy review addresses nerve research separately.

This is particularly important when a supplement blend adds several ingredients. Its label may contain a precursor alongside other compounds, so evidence and safety cannot be assessed from the large “NAD+” wording alone. Bring the complete ingredient list to the clinician or pharmacist, including the amounts and other supplements already taken.

What a useful treatment discussion looks like

Ask what a proposed intervention is intended to change: fasting glucose, HbA1c, symptoms, weight, medication requirements or a research biomarker. Then ask whether a relevant controlled human trial measured that outcome. A claim can be biologically plausible and still fail that practical test.

NIDDK emphasizes individualized food, activity and medication plans and says there is no clear proof that dietary supplements generally help manage diabetes ⁶. NCCIH likewise advises against replacing medical diabetes treatment with an unproven product ⁷. These are not reasons to conceal supplement use; they are reasons to discuss it openly and keep established care in place.

For now, the reasonable conclusion is limited: NMN has a specific prediabetes research signal, but consistent glucose control and diabetes treatment benefits remain unestablished. A product’s price, a higher blood NAD+ result or a personalized quiz cannot fill that evidence gap.